Quốc gia: Ai-len
Ngôn ngữ: Tiếng Anh
Nguồn: HPRA (Health Products Regulatory Authority)
Solifenacin succinate
Teva B.V.
G04BD; G04BD08
Solifenacin succinate
10 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
Drugs for urinary frequency and incontinence; solifenacin
Not marketed
2017-03-31
Solifenacin, DK/H/2188/001-002, 18.01.19 1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT SOLIFENACIN TEVA 5 MG FILM-COATED TABLETS SOLIFENACIN TEVA 10 MG FILM-COATED TABLETS Solifenacin succinate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Solifenacin Teva is and what it is used for 2. What you need to know before you take Solifenacin Teva 3. How to take Solifenacin Teva 4. Possible side effects 5. How to store Solifenacin Teva 6. Contents of the pack and other information 1. WHAT SOLIFENACIN TEVA IS AND WHAT IT IS USED FOR The active substance of Solifenacin Teva belongs to the group of anticholinergics. These medicines are used to reduce the activity of an overactive bladder. This enables you to wait longer before having to go to the bathroom and increases the amount of urine that can be held by your bladder. Solifenacin Teva is used to treat the symptoms of a condition called overactive bladder. These symptoms include: having a strong, sudden urge to urinate without prior warning, having to urinate frequently or wetting yourself because you could not get to the bathroom in time. Solifenacin, DK/H/2188/001-002, 18.01.19 2 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE SOLIFENACIN TEVA DO NOT TAKE SOLIFENACIN TEVA if you are allergic to solifenacin or any of the other ingredients of this medicine (listed in section 6). if you have an inability to pass water or to empty your bladder completely (urinary retention) if you have a severe stomach or bowel condition (including toxic m Đọc toàn bộ tài liệu
Health Products Regulatory Authority 09 November 2020 CRN00C0YJ Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Solifenacin Teva 10 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Solifenacin Teva 10 mg film-coated tablet: Each tablet contains 10 mg solifenacin succinate, corresponding to 7.5 mg solifenacin. Excipient with known effect Each film-coated tablet contains 78.0 mg lactose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet Solifenacin Teva 10 mg film-coated tablet: Light pink to pink, round standard convex, film coated tablet, diameter 8 mm, debossed with "S10" on one side of the tablet and plain on the other side of the tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults, including the elderly_ The recommended dose is 5 mg solifenacin succinate once daily. If needed, the dose may be increased to 10 mg solifenacin succinate once daily. _ _ _Paediatric population_ Safety and effectiveness in children have not yet been established. Therefore, solifenacin succinate should not be used in children. _Patients with renal impairment_ No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance > 30 ml/min). Patients with severe renal impairment (creatinine clearance ≤ 30 ml/min) should be treated with caution and receive no more than 5 mg once daily (see section 5.2). _ _ _Patients with hepatic impairment_ No dose adjustment is necessary for patients with mild hepatic impairment. Patients with moderate hepatic impairment (Child-Pugh score of 7 to 9) should be treated with caution and receive no more than 5 mg once daily (see section 5.2). _ _ _Potent inhibitors of cytochrome P450 3A4_ The maximum dose of solifenacin succinate should be limited to 5 mg when treated Đọc toàn bộ tài liệu